Latest Advances in Lung Cancer Research

Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.

Scientists uncover link between car fumes and lung cancer that helps explain why so many non-smokers develop disease.

AstraZeneca and Daiichi Sankyo’s Enhertu scored an accelerated FDA approval in patients with HER2-mutant NSCLC.

Study shows that smoking cessation was associated with a nearly 30% improvement in overall survival with lung cancer patients.

In SAVANNAH Phase II trial, Tagrisso + savolitinib showed a 49% objective response rate in lung cancer patients with certain MET biomarkers.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.

Younger lung cancer patients, ineligible for screening, are often diagnosed at advanced stages, unlike their older counterparts, highlighting a need for early detection methods.

Mount Sinai study finds liquid biopsies measuring PD-L1 may better predict lung cancer response to immunotherapy than traditional tumor biopsies.

Penn Medicine receives $9 million for tumor-illuminating technology to improve lung cancer surgery outcomes.

New research indicates lower income correlates with poorer lung cancer survival rates due to late diagnosis, with disparities influenced by socioeconomic status and systemic racism.

Fox Chase Cancer Center highlights advances in NSCLC treatment with immunotherapy and the promise of amivantamab for specific genetic mutations, alongside ongoing SCLC research.

Research shows combining KRAS inhibitors and immunotherapy could improve treatment for certain lung cancers, based on promising mouse studies.